IMV (Formerly Immunovaccine Inc.) to Present at the National Bank Financial Quebec Conference in Toronto
May 25 2018 - 4:05PM
IMV Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology
company, today announced that IMV Chief Executive Officer Frederic
Ors will present a corporate update at the National Bank Financial
8th Annual Quebec Conference.
Mr. Ors’ presentation will occur Wednesday, May
30, 2018 at 2:00 p.m. ET in the Museum Room in the Shangri-La Hotel
in Toronto. A copy of the presentation will be available on IMV’s
website: www.imv-inc.com
National Bank Financial Markets hosts a series
of conferences and events each year to bring together business
leaders, decision-makers and subject-matter experts to explore
strategies, trends and opportunities.
About IMVIMV Inc. is a
clinical stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
reprogramming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently conducting three Phase 2 studies
with Incyte and Merck assessing DPX-Survivac as a
combination therapy in ovarian cancer and diffuse large B-cell
lymphoma. Connect at www.imv-inc.com.
IMV Forward-Looking
StatementsThis press release contains forward-looking
information under applicable securities law. All information that
addresses activities or developments that we expect to occur in the
future is forward-looking information. Forward-looking statements
are based on the estimates and opinions of management on the date
the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. IMV Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819 E: info@imv-inc.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024